m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00254)
Name
TOK-001
Synonyms
Galeterone; 851983-85-2; Galaterone; VN/124-1; UNII-WA33E149SW; TOK 001; VN/124; WA33E149SW; (3beta)-17-(1h-benzimidazol-1-yl)androsta-5,16-dien-3-ol; (3S,8R,9S,10R,13S,14S)-17-(benzimidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Galeterone [USAN:INN]; Galeterone (USAN); TOK-001(Galeterone); SCHEMBL939234; GTPL8638; 17-(1H-Benzimidazol-1-yl)androsta-5,16-dien-3beta-ol; CHEMBL2105738; Galeterone, &gt
    Click to Show/Hide
Status
Phase 2
Structure
Formula
C26H32N2O
InChI
1S/C26H32N2O/c1-25-13-11-18(29)15-17(25)7-8-19-20-9-10-24(26(20,2)14-12-21(19)25)28-16-27-22-5-3-4-6-23(22)28/h3-7,10,16,18-21,29H,8-9,11-15H2,1-2H3/t18-,19-,20-,21-,25-,26-/m0/s1
InChIKey
PAFKTGFSEFKSQG-PAASFTFBSA-N
PubChem CID
11188409
TTD Drug ID
D0U0BU
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Androgen receptor (AR)
ETS-related transcription factor Elf-3 (ELF3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Androgen receptor (AR) is a therapeutic target for TOK-001. The ETS-related transcription factor Elf-3 (ELF3) has potential in affecting the response of TOK-001 through regulating the expression of Androgen receptor (AR). [1], [2]
References
Ref 1 ELF3 is a repressor of androgen receptor action in prostate cancer cells. Oncogene. 2014 Feb 13;33(7):862-71. doi: 10.1038/onc.2013.15. Epub 2013 Feb 25.
Ref 2 Company report (Astrazeneca)